Providing for the use of the name of the prescriber's health care practice instead of the name of the prescriber on the prescription label for certain pharmaceuticals.
Summary
SB 887 would allow a prescriber to request that the prescription label for mifepristone, misoprostol, or their generic alternatives list the name of the prescriber’s health care practice instead of the individual prescriber’s name. If the prescriber makes that request, pharmacies and other dispensers would be required to use the practice name on the label. The bill is titled the “Ensuring Reproductive Freedom by Shielding Our Providers Act,” reflecting its focus on reproductive health care and provider privacy.
The measure is narrowly tailored to a specific set of pharmaceuticals associated with medication abortion and related reproductive care. It does not change who may prescribe or dispense these drugs, but it changes how the prescriber is identified on the prescription label when the prescriber opts for practice-name identification. The bill would take effect 30 days after enactment.
Impact
SB 887 would amend Pennsylvania law to create a labeling option for prescriptions involving mifepristone, misoprostol, and generic alternatives. It would impose a new obligation on pharmacies and mail-order or internet dispensers to honor a prescriber’s request to substitute the health care practice name for the individual prescriber’s name on the label. The practical effect would be to provide an additional layer of privacy or anonymity for providers and practices involved in dispensing these medications, while leaving the underlying authority to prescribe and dispense unchanged.
Sentiment
Based on the bill’s title and sponsorship, the measure appears to have been introduced in support of reproductive health access and provider protection. The available record shows no committee transcript or vote history, so there is no documented opposition or formal support beyond the bill’s introduction. The overall framing suggests a protective, pro-reproductive-freedom intent rather than a regulatory or enforcement focus.
Contention
The likely point of contention is the balance between provider privacy and transparency on prescription labels. Supporters are likely to view the bill as a safeguard for clinicians and practices involved in abortion-related medication care, especially in a politically sensitive area. Opponents may argue that replacing the prescriber’s name with a practice name could reduce accountability or make it harder for patients, regulators, or others to identify the individual prescriber if needed. No specific objections or negotiated compromises are reflected in the available materials.
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs shall include the name of the dispensing health care practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs shall include the name of the dispensing health care practice instead of the name of the dispenser.
Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.